Relatlimab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Melanoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Non-Small Cell Lung Cancer · Phase 3

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (4)
Melanoma
NCT05625399 · Bristol-Myers Squibb
2023-03-06 – 2027-11-18 · Melanoma
What this study did
NCT05002569 · Bristol-Myers Squibb
2021-10-19 – 2025-04-02 · Melanoma
What this study did
Non-Small Cell Lung Cancer
Other / comorbidity
NCT05328908 · Bristol-Myers Squibb
2022-04-28 – 2025-07-14 · Colorectal Neoplasms
What this study did
Phase 2/3 (2)
Melanoma
Other / comorbidity
NCT05987241 · National Cancer Institute (NCI)
2024-02-02 – 2030-09-02 · Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
What this study did
Phase 2 (50)
Melanoma
NCT06999980 · Melanoma Institute Australia
2026-02-09 – 2038-01 · Cutaneous Melanoma, Mucosal Melanoma
What this study did
NCT05418972 · Melanoma Institute Australia
2023-08-14 – 2035-10 · Stage II Melanoma
What this study did
NCT07504796 · NYU Langone Health
2026-04-13 – 2031-05 · Metastatic Melanoma, Advanced Melanoma
What this study did
NCT06712927 · Stanford University
2025-08-06 – 2030-02 · Melanoma, Brain Metastases
What this study did
NCT05034536 · Massachusetts General Hospital
2022-02-07 – 2028-12-31 · Metastatic Melanoma
What this study did
NCT06295159 · H. Lee Moffitt Cancer Center and Research Institute
2024-05-17 – 2028-11 · Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
What this study did
NCT05704647 · M.D. Anderson Cancer Center
2023-02-23 – 2028-07-31 · Melanoma (Skin)
What this study did
NCT05428007 · NYU Langone Health
2023-02-02 – 2028-03-17 · Melanoma, Unresectable Melanoma
What this study did
NCT02465060 · National Cancer Institute (NCI)
2015-08-17 – 2027-12-31 · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
What this study did
NCT05912244 · Memorial Sloan Kettering Cancer Center
2023-06-09 – 2027-06-09 · Melanoma
What this study did
NCT06101134 · Bristol-Myers Squibb
2023-11-06 – 2026-12-21 · Melanoma
What this study did
NCT04552223 · Jose Lutzky, MD
2020-11-10 – 2026-01-04 · Metastatic Uveal Melanoma
What this study did
NCT02519322 · M.D. Anderson Cancer Center
2016-02-02 – 2023-01-26 · Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage III Acral Lentiginous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Acral Lentiginous Melanoma AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
What this study did
NCT03724968 · Elizabeth Davis
2019-01-17 – 2020-05-28 · Metastatic Melanoma, Advanced Melanoma, Metastatic Melanoma Stratified by MHC-II Expression
What this study did
Non-Small Cell Lung Cancer
NCT03645928 · Iovance Biotherapeutics, Inc.
2019-05-07 – 2026-02-20 · Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
What this study did
NCT04205552 · University Hospital, Essen
2020-03-04 – 2025-11-27 · NSCLC Stage II, NSCLC, Stage IIIA, NSCLC, Stage I
What this study did
NCT02750514 · Bristol-Myers Squibb
2016-05-09 – 2020-01-29 · Advanced Cancer
What this study did
Other / comorbidity
NCT07369791 · National Health Research Institutes, Taiwan
2026-12 – 2040-12 · Advanced Biliary Tract Cancer(BTC)
What this study did
NCT07644312 · Nationwide Children's Hospital
2027-03-01 – 2038-03-01 · High Grade Glioma, Diffuse Intrinsic Pontine Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma, Replication Repair Deficient
What this study did
NCT06288191 · Melanoma Institute Australia
2024-06-21 – 2036-07 · Cutaneous Squamous Cell Carcinoma
What this study did
NCT06151236 · Melanoma Institute Australia
2024-03-11 – 2034-04 · Merkel Cell Carcinoma
What this study did
NCT03521830 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2018-11-27 – 2032-07 · Basal Cell Carcinoma
What this study did
NCT03026140 · The Netherlands Cancer Institute
2017-03-29 – 2032-03-01 · Colon Carcinoma
What this study did
NCT06816927 · Duke University
2025-11-28 – 2031-06-01 · Newly Diagnosed Glioblastoma
What this study did
NCT06715241 · ARCAGY/ GINECO GROUP
2024-12-11 – 2030-12-31 · LOCALLY ADVANCED CERVICAL CANCERS
What this study did
NCT03899155 · Bristol-Myers Squibb
2019-08-09 – 2029-08-25 · Cancer
What this study did
NCT06325683 · National Cancer Institute (NCI)
2024-11-08 – 2029-07-15 · Progressive Glioblastoma, Recurrent Glioblastoma
What this study did
NCT06029270 · National Cancer Institute (NCI)
2024-07-15 – 2029-04-30 · Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
What this study did
NCT05148546 · The Netherlands Cancer Institute
2022-04-28 – 2029-04 · Renal Cell Carcinoma
What this study did
NCT06708949 · M.D. Anderson Cancer Center
2025-03-20 – 2028-12-15 · Renal Cell Carcinoma, Clear Cell
What this study did
NCT06237920 · The Netherlands Cancer Institute
2024-02-19 – 2028-08-01 · Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Urogenital Diseases, Urinary Bladder Diseases, Male Urogenital Diseases, Urinary Bladder Neoplasm, Antineoplastics Toxicity
What this study did
NCT06624475 · University of California, San Diego
2025-08-21 – 2028-05 · Basal Cell Carcinoma
What this study did
NCT04080804 · Dan Zandberg
2019-12-20 – 2028-04-13 · Head and Neck Squamous Cell Carcinoma (HNSCC)
What this study did
NCT04204837 · Salzburger Landeskliniken
2017-03-06 – 2027-12 · Squamous Cell Carcinoma of the Skin
What this study did
NCT03607890 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2018-11-16 – 2027-10 · Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors
What this study did
NCT05347212 · M.D. Anderson Cancer Center
2022-09-22 – 2027-07-16 · Carcinomas, Renal Medullary Carcinoma
What this study did
NCT04953104 · M.D. Anderson Cancer Center
2021-09-21 – 2026-12-31 · Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma, Unresectable Urothelial Carcinoma
What this study did
NCT04095208 · Institut Bergonié
2020-02-27 – 2026-03-29 · Soft Tissue Sarcoma Adult, Advanced Cancer
What this study did
NCT04913922 · Ludwig-Maximilians - University of Munich
2021-05-05 – 2026-03 · Acute Myeloid Leukemia
What this study did
NCT04567615 · Bristol-Myers Squibb
2021-02-04 – 2025-11-19 · Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma, Liver Cell Carcinoma, Adult
What this study did
NCT04062656 · University Hospital, Essen
2019-09-26 – 2025-06-01 · Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction
What this study did
NCT03704077 · Bristol-Myers Squibb
2019-10-31 – 2024-09-30 · Gastric Cancer, Cancer of the Stomach, Stomach Cancer, Gastroesophageal Junction
What this study did
NCT03642067 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2019-02-12 – 2024-09-18 · Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma
What this study did
NCT04326257 · Dan Zandberg
2020-05-14 – 2024-08-12 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT03623854 · Jonsson Comprehensive Cancer Center
2019-04-03 – 2023-09-28 · Chordoma, Locally Advanced Chordoma, Metastatic Chordoma, Unresectable Chordoma
What this study did
NCT06400264 · National Cancer Institute (NCI)
2022-02-22 – 2023-01-17 · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
What this study did
NCT02935634 · Bristol-Myers Squibb
2016-11-29 – 2022-05-11 · Advanced Gastric Cancer
What this study did
NCT02996110 · Bristol-Myers Squibb
2017-02-02 – 2021-11-23 · Advanced Cancer
What this study did
Phase 1/2 (13)
Melanoma
NCT06683755 · M.D. Anderson Cancer Center
2024-12-31 – 2032-08-16 · Melanoma
What this study did
NCT07281924 · University of Wisconsin, Madison
2026-11 – 2030-12 · Metastatic Melanoma, Liver Metastases
What this study did
Other / comorbidity
NCT06963905 · Yale University
2025-12-29 – 2030-12 · Metastatic Triple-negative Breast Cancer
What this study did
NCT03610711 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2019-03-06 – 2027-12 · Gastroesophageal Cancer, Immune Checkpoint Inhibition
What this study did
NCT05255601 · Bristol-Myers Squibb
2022-09-13 – 2025-12-03 · Lymphoma, Non-Hodgkin, Hodgkin Disease
What this study did
NCT05337137 · Bristol-Myers Squibb
2022-05-05 – 2025-11-18 · Carcinoma, Hepatocellular
What this study did
NCT03459222 · Bristol-Myers Squibb
2018-05-30 – 2025-02-19 · Advanced Cancer
What this study did
NCT04150965 · Multiple Myeloma Research Consortium
2020-07-10 – 2024-08-30 · Multiple Myeloma, Relapsed Refractory Multiple Myeloma
What this study did
NCT04611126 · Inge Marie Svane
2021-04-22 – 2024-03-03 · Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer, Peritoneal Cancer
What this study did
NCT03310619 · Celgene
2017-12-20 – 2023-02-15 · Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
What this study did
NCT02488759 · Bristol-Myers Squibb
2015-10-13 – 2022-10-24 · Various Advanced Cancer
What this study did
NCT02061761 · Bristol-Myers Squibb
2014-03-13 – 2022-02-16 · Hematologic Neoplasms
What this study did
Phase 1 (12)
Melanoma
NCT04697576 · Carlo Contreras
2021-10-20 – 2027-12-31 · Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
What this study did
NCT05704933 · H. Lee Moffitt Cancer Center and Research Institute
2023-06-06 – 2024-08-20 · Metastatic Melanoma, Metastasis to Brain
What this study did
NCT04935229 · TriSalus Life Sciences, Inc.
2021-08-02 – 2024-07-17 · Metastatic Uveal Melanoma in the Liver
What this study did
Non-Small Cell Lung Cancer
NCT05176483 · Exelixis
2021-12-14 – 2030-06-28 · Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
What this study did
Other / comorbidity
NCT04658147 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2021-05-28 – 2030-06-01 · Hepatocellular Carcinoma
What this study did
NCT03044613 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2017-07-11 – 2027-08 · Gastric Cancer, Esophageal Cancer, GastroEsophageal Cancer
What this study did
NCT02966548 · Bristol-Myers Squibb
2017-01-04 – 2024-07-09 · Cancer
What this study did
NCT05498480 · Bristol-Myers Squibb
2022-07-27 – 2024-01-18 · Advanced Solid Tumors
What this study did
NCT02658981 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2016-08-24 – 2023-10-03 · Glioblastoma, Gliosarcoma, Recurrent Brain Neoplasm
What this study did
NCT04112498 · Bristol-Myers Squibb
2019-10-01 – 2023-02-27 · Cancer
What this study did
NCT03335540 · Bristol-Myers Squibb
2018-05-07 – 2021-08-25 · Advanced Cancer
What this study did
Phase 4 (1)
Melanoma
NCT07459543 · Bristol-Myers Squibb
2026-11-15 – 2029-05-28 · Unresectable Melanoma, Metastatic Melanoma
What this study did
Used as active comparator (5)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (4)
Melanoma
NCT06246916 · Regeneron Pharmaceuticals
2024-09-09 – 2033-07-10 · Melanoma
What this study did
NCT06743126 · Immatics US, Inc.
2025-01-14 – 2032-08-12 · Melanoma, Cutaneous Malignant, Mucosal Melanoma
What this study did
NCT06264180 · Replimune, Inc.
2024-07-11 – 2031-03-31 · Advanced Melanoma
What this study did
NCT06112314 · Immunocore Ltd
2024-06-05 – 2027-10-16 · Advanced Melanoma
What this study did
Phase 2/3 (1)
Melanoma
NCT06624644 · Linnaeus Therapeutics, Inc.
2025-08-06 – 2031-02 · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma, Unresectable Melanoma
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Melanoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Relatlimab: this drugApprovedMonoclonal antibodyLAG-3Reliable signal
NCT03470922: Progression Free Survival (PFS) (From randomization to date of first documented tumor progression or death (up to approximately 33 months)): Arm A: Relatlimab + Nivolumab 10.12 Months (95% CI 6.37 to 15.74) | Arm B: Nivolumab 4.63 Months (95% CI 3.38 to 5.62)
Aldesleukin (Proleukin)ApprovedRecombinant Cytokine (il-2)Interleukin-2 receptor (IL-2R)not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BinimetinibApprovedSmall moleculeMEK1/2Partial signal
NCT01763164: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)): Binimetinib (MEK162) 2.83 Months (95% CI 2.76 to 3.55) | Dacarbazine 1.51 Months (95% CI 1.48 to 1.71)
CobimetinibApprovedSmall moleculeMEK1/2Reliable signalNo reviewed efficacy summary in this indication
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Reliable signal
NCT01597908: Overall Survival (OS) (From the date of randomization until date of death due to any cause (up to approximately 6 years)): Dabrafenib Plus Trametinib 26 Months (95% CI 22.1 to 33.8) | Vemurafenib 17.8 Months (95% CI 15.6 to 20.7)
NCT01584648: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)): Dabrafenib + Trametinib 10.2 Months (95% CI 8.1 to 12.8) | Dabrafenib + Placebo 8.8 Months (95% CI 5.9 to 9.3)
EncorafenibApprovedSmall moleculeBRAF V600EPartial signalNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptorPartial signal
NCT01359956: Overall survival, interferon alfa-2b added vs not added to dacarbazine-based chemotherapy (2x2 factorial): HR 0.92 (95% CI 0.70 to 1.20), p=0.68 (Daponte et al., J Transl Med 2013). missed
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT00094653: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone (From randomization until the end of the study, which was defined as the time at which 481 deaths were observed (264 weeks)): Ipilimumab Plus gp100 9.95 months (95% CI 8.48 to 11.5) | gp100 6.44 months (95% CI 5.49 to 8.71)
Lifileucel (Amtagvi)ApprovedCell therapyTumor-infiltrating lymphocytes (polyclonal tumor antigens)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02388906: Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09)
NCT01721746: CheckMate 037 coprimaries: objective response rate 31.7% (95% CI 23.5 to 40.8) in the first 120 nivolumab patients vs 10.6% (3.5 to 23.1) with investigator-choice chemotherapy at the interim analysis, reported without a between-group p-value; overall survival median 16 vs 14 months (HR 0.95, 95.54% CI 0.73 to 1.24), no difference (Weber, Lancet Oncol 2015; Larkin, JCO 2018). missed
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
TrametinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
VemurafenibApprovedSmall moleculeBRAF (V600 mutant)Partial signalNo reviewed efficacy summary in this indication
Vusolimogene Oderparepvec (Tudriqev)ApprovedOncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
CemiplimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
FianlimabPhase 3Monoclonal antibodyLAG-3not yet gradedNo reviewed efficacy summary in this indication
Intismeran AutogenePhase 3VaccinePatient-specific tumor neoantigens (personalized, up to 34 per patient)not yet gradedNo reviewed efficacy summary in this indication
Tebentafusp-Tebn (KIMMTRAK)Phase 3Protein / enzyme therapeuticgp100-HLA-A*02:01 x CD3Partial signalNo reviewed efficacy summary in this indication
LNS8801Phase 2/3Small moleculeGPER (G protein-coupled estrogen receptor)not yet gradedNo reviewed efficacy summary in this indication
ResiquimodPhase 2/3Small moleculeToll-like receptor 7 and 8 (TLR7/8)not yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 2Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
VSV-IFNβ-NISPhase 2Oncolytic virusOncolytic VSV expressing interferon-beta and NISnot yet gradedNo reviewed efficacy summary in this indication
EvalstotugPhase 1/2Biologic (subtype unspecified)CTLA-4not yet gradedNo reviewed efficacy summary in this indication
OBX-115Phase 1/2Cell therapyIL-15 receptor signalingnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
GSK2831781
Discontinued
Monoclonal antibodyLAG-3
not yet graded(overall)
No reviewed efficacy summary in this indication
NaporafenibDiscontinuedSmall moleculePan-RAFnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(34 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Relatlimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (6)
November 2026 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2026-11 · NCT06712927 · CT.gov ↗
What to watch
December 2026 (5)
Phase 1/2Gastroesophageal Cancer, Immune Checkpoint InhibitionActive not recruiting
Est. primary completion 2026-12 · NCT03610711 · CT.gov ↗
What to watch
Phase 2Squamous Cell Carcinoma of the SkinRecruiting
Est. primary completion 2026-12 · NCT04204837 · CT.gov ↗
What to watch
Phase 2Merkel Cell CarcinomaRecruiting
Est. primary completion 2026-12 · NCT06151236 · CT.gov ↗
What to watch
Phase 2Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Neoplasms, Female Urogenital Diseases …Active not recruiting
Est. primary completion 2026-12-01 · NCT06237920 · CT.gov ↗
What to watch
Phase 2Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma …Active not recruiting
Est. primary completion 2026-12-31 · NCT04953104 · CT.gov ↗
What to watch
2027 (9)
January 2027 (1)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-31 · NCT05176483 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1Gastric Cancer, Esophageal Cancer, GastroEsophageal CancerActive not recruiting
Est. primary completion 2027-03 · NCT03044613 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-06-09 · NCT05912244 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-06-30 · NCT05034536 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Basal Cell CarcinomaRecruiting
Est. primary completion 2027-07 · NCT03521830 · CT.gov ↗
What to watch
Phase 2Carcinomas, Renal Medullary CarcinomaActive not recruiting
Est. primary completion 2027-07-16 · NCT05347212 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1MelanomaRecruiting
Est. primary completion 2027-09-30 · NCT04697576 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H TumorsActive not recruiting
Est. primary completion 2027-10 · NCT03607890 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-12-31 · NCT02465060 · CT.gov ↗
What to watch
2028 (6)
March 2028 (2)
Phase 2MelanomaRecruiting
Est. primary completion 2028-03 · NCT06999980 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2028-03-17 · NCT05428007 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Basal Cell CarcinomaRecruiting
Est. primary completion 2028-05 · NCT06624475 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2028-07-31 · NCT05704647 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2028-11 · NCT06295159 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Renal Cell Carcinoma, Clear CellActive not recruiting
Est. primary completion 2028-12-15 · NCT06708949 · CT.gov ↗
What to watch
2029 (5)
April 2029 (1)
Phase 2Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8Recruiting
Est. primary completion 2029-04-30 · NCT06029270 · CT.gov ↗
What to watch
May 2029 (2)
Phase 2MelanomaRecruiting
Est. primary completion 2029-05 · NCT07504796 · CT.gov ↗
What to watch
Phase 4MelanomaNot yet recruiting
Est. primary completion 2029-05-26 · NCT07459543 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Newly Diagnosed GlioblastomaRecruiting
Est. primary completion 2029-06-01 · NCT06816927 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2CancerRecruiting
Est. primary completion 2029-08-25 · NCT03899155 · CT.gov ↗
What to watch
2030 (6)
July 2030 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-07-30 · NCT06561386 · CT.gov ↗
What to watch
August 2030 (1)
Phase 1/2MelanomaRecruiting
Est. primary completion 2030-08-16 · NCT06683755 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2/3Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma …Recruiting
Est. primary completion 2030-09-02 · NCT05987241 · CT.gov ↗
What to watch
December 2030 (3)
Phase 1/2Metastatic Triple-negative Breast CancerRecruiting
Est. primary completion 2030-12 · NCT06963905 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2030-12 · NCT07281924 · CT.gov ↗
What to watch
Phase 2LOCALLY ADVANCED CERVICAL CANCERSActive not recruiting
Est. primary completion 2030-12-31 · NCT06715241 · CT.gov ↗
What to watch
2032 (1)
March 2032 (1)
Phase 2Colon CarcinomaRecruiting
Est. primary completion 2032-03-01 · NCT03026140 · CT.gov ↗
What to watch
2033 (1)
March 2033 (1)
Phase 2High Grade Glioma, Diffuse Intrinsic Pontine Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma, Replication Repair DeficientNot yet recruiting
Est. primary completion 2033-03-01 · NCT07644312 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 February 2025Topline resultPhase 3 RELATIVITY-098 (NCT05002569) did not meet its primary endpoint of recurrence-free survival
Bristol Myers Squibb · Source ↗